PROCEPT BioRobotics (PRCT) shares plummeted 5.80% in after-hours trading on Tuesday, despite the surgical robotics company reporting better-than-expected third-quarter results. The sharp decline appears to be driven by the company's 2026 revenue guidance, which fell short of investor expectations.

For the third quarter of 2025, PROCEPT BioRobotics reported revenue of $83.3 million, surpassing analysts' expectations of $80.9 million. The company's adjusted EBITDA loss of $7.4 million also beat the estimated loss of $10.2 million. However, these positive results were overshadowed by the company's forward-looking guidance.

While PROCEPT BioRobotics maintained its fiscal year 2025 revenue guidance of approximately $325.5 million, representing a 45% year-over-year growth, the company's newly issued fiscal year 2026 revenue guidance disappointed investors. PROCEPT projects 2026 revenue to be in the range of $410 million to $430 million, indicating a growth rate of 26% to 32% compared to the 2025 guidance. This potential slowdown in growth rate appears to be the key factor behind the stock's significant after-hours decline, as investors had likely anticipated more aggressive growth projections for the coming year.